Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    15552715 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Active, not recruiting Efficacy and Safety Study of Omalizumab (Xolair®) to Treat Chronic Urticaria
Condition: Chronic Urticaria
Interventions: Biological: Omalizumab;   Biological: Placebo
2 Recruiting Efficacy Study of Omalizumab in Cholinergic Urticaria
Condition: Cholinergic Urticaria
Interventions: Biological: Active;   Biological: Placebo;   Biological: Open labeled

Indicates status has not been verified in more than two years